Literature DB >> 11016544

Nicotinic receptor losses in dementia with Lewy bodies: comparisons with Alzheimer's disease.

R T Rei1, M N Sabbagh, J Corey-Bloom, P Tiraboschi, L J Thal.   

Abstract

We sought to delineate differences between alpha7 nicotinic acetylcholine receptor (nAChR) levels in Alzheimer's disease (AD), dementia with Lewy bodies (DLB) and age matched controls, as well as the correlations between alpha7 or non-alpha7 nAChR levels and synaptophysin (Syn) or choline acetyltransferase (ChAT) in DLB. Mean bungarotoxin (Bgt) binding was 2.7 - 1.1 for controls, 2.4 +/- 1.0 for AD and 1.4 +/- 0.5 for DLB. There were significant decreases in Bgt binding for the DLB group compared to either controls or AD. Mean epibatidine (Epi) binding was 14.8 +/- 3.2 for controls, 6.3 +/- 3.2 for AD and 7.1 +/- 2.4 fmoles/mg protein for DLB. Epi binding in both the AD and DLB groups was significantly lower than in the controls. Although Syn loss correlated with the decrease in Epi binding in both diseases, declining ChAT levels correlated with Epi binding only in DLB. These data demonstrate a different pattern of nAChR loss in AD and DLB that may, in part, explain some of the differences in the two phenotypes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11016544     DOI: 10.1016/s0197-4580(00)00168-8

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  9 in total

1.  Some properties of human neuronal alpha 7 nicotinic acetylcholine receptors fused to the green fluorescent protein.

Authors:  Eleonora Palma; Anna M Mileo; Ataulfo Martinez-Torres; Fabrizio Eusebi; Ricardo Miledi
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

2.  Endogenous signaling through alpha7-containing nicotinic receptors promotes maturation and integration of adult-born neurons in the hippocampus.

Authors:  Nolan R Campbell; Catarina C Fernandes; Andrew W Halff; Darwin K Berg
Journal:  J Neurosci       Date:  2010-06-30       Impact factor: 6.167

Review 3.  Biochemical and pathological correlates of cognitive and behavioural change in DLB/PDD.

Authors:  Paul T Francis
Journal:  J Neurol       Date:  2009-08       Impact factor: 4.849

Review 4.  Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.

Authors:  David G Wilkinson; Paul T Francis; Elias Schwam; Jennifer Payne-Parrish
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

5.  Meta-analysis of synaptic pathology in Alzheimer's disease reveals selective molecular vesicular machinery vulnerability.

Authors:  Martijn C de Wilde; Cassia R Overk; John W Sijben; Eliezer Masliah
Journal:  Alzheimers Dement       Date:  2016-01-14       Impact factor: 21.566

6.  Effects of cholinesterase inhibitors on rat nicotinic receptor levels in vivo and in vitro.

Authors:  Richard T Reid; Marwan N Sabbagh
Journal:  J Neural Transm (Vienna)       Date:  2008-08-26       Impact factor: 3.575

7.  Synaptic phosphorylated α-synuclein in dementia with Lewy bodies.

Authors:  Martí Colom-Cadena; Jordi Pegueroles; Abigail G Herrmann; Christopher M Henstridge; Laia Muñoz; Marta Querol-Vilaseca; Carla San Martín-Paniello; Joan Luque-Cabecerans; Jordi Clarimon; Olivia Belbin; Raúl Núñez-Llaves; Rafael Blesa; Colin Smith; Chris-Anne McKenzie; Matthew P Frosch; Allyson Roe; Juan Fortea; Jordi Andilla; Pablo Loza-Alvarez; Ellen Gelpi; Bradley T Hyman; Tara L Spires-Jones; Alberto Lleó
Journal:  Brain       Date:  2017-12-01       Impact factor: 13.501

Review 8.  The nicotinic acetylcholine receptor: smoking and Alzheimer's disease revisited.

Authors:  Mona Mehta; Abdu Adem; Maninder S Kahlon; Marwan N Sabbagh
Journal:  Front Biosci (Elite Ed)       Date:  2012-01-01

Review 9.  Cholinergic Modulation of Glial Function During Aging and Chronic Neuroinflammation.

Authors:  Rashmi Gamage; Ingrid Wagnon; Ilaria Rossetti; Ryan Childs; Garry Niedermayer; Rose Chesworth; Erika Gyengesi
Journal:  Front Cell Neurosci       Date:  2020-10-15       Impact factor: 5.505

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.